Jane U. Adetifa

Learn More
BACKGROUND Measles vaccine in early infancy followed by a dose at 9 months of age protects against measles and enhances child survival through non-specific effects. Little is known of immune responses in the short or long term after booster doses. METHODS Infants were randomized to receive measles vaccine at 9 months of age (group 1) or 4 and 9 months of(More)
INTRODUCTION In 2011, two years after the introduction of 7-valent Pneumococcal conjugate vaccine (PCV7), the Gambian immunization programme replaced PVC7 with PCV13 (13-valent). Our objective was to assess the additional impact of PCV13 on prevalence of pneumococcal nasopharyngeal carriage. METHODS We recruited healthy Gambian infants who had received(More)
  • 1